Results 11 to 20 of about 5,752,243 (395)
Cancer Imaging, 2004 Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the current status and highlights how an understanding of both is necessary for optimum management.
S. Vincent Rajkumar, Robert A. Kyle
+14 more sources
New England Journal of Medicine, 2011 Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
PALUMBO, Antonio, Anderson K.
+9 more sources
Nature Communications, 2021 BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined.
M. Samur +14 more
semanticscholar +1 more source
Journal of the American Medical Association (JAMA), 2022 What Is Multiple Myeloma? Cancer starts when cells begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas.
Juliet Silberstein +2 more
semanticscholar +1 more source
Epidemiology, Staging, and Management of Multiple Myeloma
Medical Science, 2021 Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the ...
S. Padala +7 more
semanticscholar +1 more source
Journal of the American Academy of Physician Assistants, 2015 This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed.
Tonon G., Anderson K. C.
+11 more sources
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
Cancers, 2021 Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant plasma cell proliferation in the bone marrow (BM) and constitutes the second most common hematological disease after non-Hodgkin lymphoma.
A. García-Ortiz +6 more
semanticscholar +1 more source
Cancer Medicine, 2022 Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen +8 more
doaj +1 more source
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
American journal of hematology/oncology, 2020 Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar +1 more source
MRI in multiple myeloma : a pictorial review of diagnostic and post-treatment findings [PDF]
, 2016 Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group.
A Baur +51 more
core +2 more sources